Bristol-Myers Squibb's Sprycel® (dasatinib) Tablets Now Approved in Combination with Chemotherapy in Certain Pediatric Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia - Business Wire

Bristol-Myers Squibb's Sprycel® (dasatinib) Tablets Now Approved in Combination with Chemotherapy in Certain Pediatric Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia  Business Wire

Sprycel is the first and only second-generation tyrosine kinase inhibitor for pediatric patients for the treatment of newly diagnosed Philadelphia ...



Comments

Popular posts from this blog

4 Symptoms of Stress You Should Never Ignore - AARP

Dyspnea (Shortness of Breath): Causes, Symptoms & Treatment - my.clevelandclinic.org

Top pulmonology news from July: FDA updates, antibiotics in cystic fibrosis, treatment of COPD exacerbations - Healio